Mapping of sub-networks in the EGFR-MAPK pathway in different breast cancer cell lines reveals that PAK1 may be a marker for sensitivity to MEK inhibitors

Barbara L Weber

Carolyn L Talcott

Jeffrey R Jackson

Joe W Gray

Keith R Laderoute

Laura M Heiser

Merrill Knapp

Nicholas J Wang

Paul T Spellman

Ph.D Paul T Spellman

Richard F Wooster

Safiyyah Ziyad

Sylvie Laquerre

Wen-Lin Kuo

Yinghui Guan

Zhi Hu

CiteSeerX

Crossref

Springer - Publisher Connector

PubMed Central

UNT Digital Library

English

10:R31 ries of high density oligonucleotide array probe level data. Biostatistics

A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol

Aalto Y: Online access to CGH data of DNA sequence copy number changes.

AL: The largescale organization of metabolic networks.

Albertson DG: Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene

Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baldari CT: SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem

Bokoch GM: p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol

Catling AD: MEK1 activation by PAK: a novel mechanism. Cell Signal

CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer.

CC: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res

Cluster analysis and display of genome-wide expression patterns.

Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol

der: A method to identify significant clusters in gene expression data.

DG: Breast tumor copy number aberration phenotypes and genomic instability.

Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA

E: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res

E: Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol

El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res

Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet

Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA

Faham M: Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol

Favre G: Loss of RhoB expression in human lung cancer progression. Clin Cancer Res

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

FG: Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene

Formal executable models of cell signaling primatives.

Gallick GE: SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell

Graff JR: Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res

Greenberg ME: EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell

Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet

Hoek JB: Quantification of short term signaling by the epidermal growth factor receptor.

Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol

Human Tumor Cell Line Screen Process Website [http://dtp.nci.nih.gov/branches/btb/ivclsp.html]

Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg

Java Treeview--extensible visualization of microarray data. Bioinformatics

JR: Genomic signatures to guide the use of chemotherapeutics. Nat Med

JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell

JW: Chromosome aberrations in solid tumors. Nat Genet

KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev

Laderoute K: Pathway logic modeling of protein functional domains in signal transduction.

Lauffenburger D: Building with a scaffold: emerging strategies for high- to low-level cellular modeling. Trends Biotechnol

Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell

Molecular portraits of human breast tumours. Nature

MP: Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.

MP: Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.

N: BRAF mutation predicts sensitivity to MEK inhibition. Nature

NE: The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDAMB231. Nucleic Acids Res

NE: The loss of estrogen and progesterone receptor gene expression in human breast cancer.

Nets: Properties, Analysis and Applications

Omata M: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res

Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature

Overview of cancer epigenetics. Semin Hematol

p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts.

PE: PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene

Perou CM: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res

PK: Rare cancer-specific mutations in PIK3CA show gain of function.

Potti A: Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet

Prendergast GC: RhoB in cancer suppression. Histol Histopathol

prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.

R: p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells.

R: PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene

R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science

Recent progress in targeting the Raf/ MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol

Rho GTPases and the control of cell behaviour. Biochem Soc Trans

Ridley AJ: Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res

Rowinsky E: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI), shows evidence of good tolerability and activity: final results from a Phase I study. Proc Am Soc Clin Oncol

Rowinsky E: Phase I study of oral ZD1839 a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFRTK): evidence of good tolerability and activity. Clin Cancer Res

Rules for modeling signal-transduction systems. Sci STKE

Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade.

Sebti SM: EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene

Shakhnovich EI: Expanding protein universe and its origin from the biological Big Bang. Proc Natl Acad Sci USA

Shore SK: Src in human carcinogenesis. Front Biosci

SJ: c-Src and cooperating partners in human cancer. Cancer Cell

Slamon DJ: Multinational study of the efficacy and safety of humanized antiHER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol

Sonmez K: Pathway logic: symbolic analysis of biological signaling.

Symbolic modeling of signal transduction in pathway logic.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene

The EGF receptor family as targets for cancer therapy. Oncogene

The genomic landscapes of human breast and colorectal cancers. Science

Thiagarajan PS: A decompositional approach to parameter estimation in pathway modeling: a case study of the Akt and MAPK pathways and their crosstalk. Bioinformatics

Tiwari A: Symbolic systems biology: Hybrid modeling and analysis of biological networks.

Using Bayesian networks to analyze expression data.

Using graphical models and genomic expression data to statistically validate models of genetic regulatory networks.

Vander: Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci USA

Weinberg RA: The hallmarks of cancer. Cell

Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol

Integrated analysis of breast cancer cell lines reveals unique signaling pathways